Micromedex® Compendia Resources
Through the process established by the Centers for Medicare and Medicaid Services (CMS), Micromedex® DRUGDEX® is recognized by CMS as a compendium for the determination of payment for medically-accepted off-label uses for anti-cancer regimens. Effective January 1, 2010, new requirements were implemented that include a provision for providing transparency of processes used to evaluate therapies and to identify potential conflicts of interest. Specifically, publishers of compendia must now make the following information available via their public websites:
- Criteria used to evaluate the request (therapy)
- Disclosure of evidence considered
- Meeting minutes and records of votes for disposition of the request (therapy)
- Names of individuals who have substantively participated in the development of the compendia recommendations and disclosure of any potential conflicts of interest
To meet these requirements, documents detailing this information for each drug/off-label use pair published on or after January 1, 2010 are posted below. Information is organized by drug name, with the document title indicating the off-label use. Further transparency regarding Micromedex Off-Label processes can be found in the Micromedex Compendia Uses Policy.
Information is organized by drug name, with the document title indicating the off-label use.
- Chronic lymphocytic leukemia
- Graft versus host disease, in patients receiving allogeneic stem cell transplant for hematologic malignancies, steroid-refractory
- (PEDIATRIC) Graft versus host disease, in patients receiving allogeneic stem cell transplant for hematologic malignancies, steroid-refractory
- Primary cutaneous T-cell lymphoma, Relapsed or refractory
- Nonsquamous nonsmall cell neoplasm of lung, stage IIIB/IV or recurrent disease with EGFR exon 19 deletion or exon 21 mutation, first-line therapy in combination with erlotinib
- Mesothelioma
- Nonsquamous nonsmall cell neoplasm of lung Stage IIIB/IV, first-line therapy in combination with pemetrexed and carboplatin
- Necrosis of central nervous system due to exposure to ionizing radiation
- Extensive stage small cell lung cancer, First-line, in combination with chemotherapy
- Nonsquamous nonsmall cell neoplasm of lung; Stage IIIB/IV, continuation maintenance therapy as a single-agent following platinum-based, first-line therapy
- Cancer of cervix, recurrent, persistent, or metastatic
- Colon cancer, adjuvant therapy in combination with fluorouracil, leucovorin, and oxaliplatin
- Gastric cancer, advanced, first-line therapy in combination with fluoropyrimidine-based chemotherapy
- Glioblastoma multiforme of brain, newly diagnosed
- Liver carcinoma, advanced
- Metastatic breast cancer, HER2-negative, first-line therapy in combination with chemotherapy (except paclitaxel)
- Metastatic breast cancer, HER2-negative, as second-line therapy in combination with other chemotherapy
- Nonsquamous non-small cell lung cancer, advanced or recurrent, first-line therapy in combination with cisplatin and gemcitabine
- Ovarian cancer, advanced, first-line therapy in combination with carboplatin and paclitaxel
- Metastatic colorectal cancer, maintenance therapy following oxaliplatin-based induction chemotherapy in previously untreated patients
- Malignant tumor of breast; Early, HER2-negative, postoperative monotherapy in patients with residual disease after neoadjuvant anthracycline/taxane-based treatment
- Triple-negative breast cancer; Early, adjuvant therapy
- Gastric cancer, stage ll to lllB, adjuvant therapy in combination with oxaliplatin
- Rectal cancer, locally advanced, adjuvant or neoadjuvant therapy, in combination with radiotherapy
- Stage lll colon cancer, adjuvant, in combination with oxaliplatin
- Malignant tumor of urinary bladder, Muscle invasive, as neoadjuvant combination chemotherapy
- Malignant tumor of thyroid gland, Advanced, in combination with doxorubicin
- Non-Hodgkin lymphoma, Relapsed or refractory, as part of the DHAP or ESHAP chemotherapy regimen
- Pancreatic cancer, locally advanced or metastatic, first-line therapy in combination with gemcitabine
- Triple negative breast cancer
- Non-small cell lung cancer, metastatic with BRAF V600E mutation, in previously treated patients as monotherapy or in combination with trametinib
- Malignant melanoma, Adjuvant, following complete resection of Stage III (with lymph node involvement greater than 1 mm) disease with BRAF V600E or V600K mutation, in combination with trametinib
- Malignant tumor of breast, advanced, hormone receptor-negative, HER2 positive, in trastuzumab-containing regimens
- Hodgkin’s disease (clinical), Relapsed or refractory, in patients who had failed or were ineligible for autologous hematopoietic stem cell transplant or after failure of a gemcitabine-, vinorelbine-, or vinblastine containing regimen
- Waldenstrom macroglobulinemia, relapsed or refractory
- Malignant tumor of nasopharynx; Recurrent or metastatic, first-line therapy in combination with cisplatin
- Malignant tumor of nasopharynx; Locoregionally advanced disease, as induction therapy before chemoradiation
- Non-small cell lung cancer; Stage IIIB/IV, continuation maintenance therapy as a single agent following first-line induction therapy with cisplatin and gemcitabine
- Mantle cell lymphoma, relapsed or refractory, as combination therapy
- Ovarian cancer, Advanced, first-line therapy in combination with paclitaxel and carboplatin
- Peripheral t-cell lymphoma
- POEMS syndrome
- Chronic lymphoid leukemia, disease; Maintenance, after chemotherapy
- AL amyloidosis; Relapsed or refractory, combination therapy
- Myelodysplastic syndrome, transfusion-dependent anemia in patients at low –r intermediate-1 risk without deletion 5q abnormality
- Non-Hodgkin lymphoma, in combination with rituximab
- Myelofibrosis
- Non-small cell lung cancer, metastatic or recurrent, PD-L1 expression, first-line treatment, with no EGFR or ALK tumor aberrations
- Malignant melanoma, adjuvant, following complete resection of Stage IIIB, IIIC, or IV (resected distant metastases) disease
- Malignant mesothelioma of pleura; Progressive or recurrent disease following platinum-based chemotherapy
- Malignant tumor of ovary, recurrent, platinum-sensitive, with at least 2 prior platinum-based chemotherapy regimens, as maintenance therapy
- Metastatic breast cancer, HER2-negative, germline BRCA mutation-positive
- Metastatic prostate cancer; Castration-resistant, previously treated with chemotherapy
- Malignant tumor of pancreas; Metastatic, deleterious or suspected deleterious germline BRCA1 or BRCA2 mutation, as maintenance therapy in patients who did not progress during first-line platinum-based chemotherapy
- Malignant tumor of breast; Early, HER2-negative, germline BRCA mutation-positive, high-risk, after (neo)adjuvant chemotherapy and local treatment (radiation) therapy
- Mantle cell lymphoma; As combination therapy
- Advanced or metastatic biliary tract cancer, in combination with gemcitabine
- Metastatic pancreatic adenocarcinoma, first-line treatment, in combination with 5-fluorouracil, leucovorin, and irinotecan
- Advanced or metastatic biliary tract cancer, in combination with gemcitabine
- Squamous cell carcinoma of head and neck
- Metastatic colorectal cancer, wild-type KRAS mutation, first-line therapy, in combination with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4 regimen)
- Metastatic colorectal cancer, wild-type KRAS mutation, second-line therapy following fluoropyrimidine-containing chemotherapy, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen)
- Burkitt’s lymphoma (clinical) in combination with chemotherapy
- Mantle cell lymphoma untreated, maintenance therapy
- Chronic lymphoid leukemia, disease maintenance, following rituximab-containing chemotherapy
- Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia; CD20-positive, in combination with chemotherapy
- Immune thrombocytopenia; In combination with a corticosteroid
- Immune thrombocytopenia, previously treated [pediatric]
- Mantle cell lymphoma, untreated, induction therapy, in combination with anthracycline-based regimens
- Post-transplant lymphoproliferative disorder [pediatric patients]
- Thrombotic thrombocytopenic purpura, in combination with plasma exchange
- Gastrointestinal stromal tumor Advanced or metastatic disease, after failing treatment with imatinib and sunitinib
- Malignant tumor of ovary; Primary peritoneal cancer, maintenance therapy
- Renal cell carcinoma, Adjuvant therapy following nephrectomy in patients at high risk for recurrence
- Acute myeloid leukemia, disease; FLT3-ITD mutation-positive, maintenance therapy following allogeneic HSCT
- Melanoma, unresectable or metastatic, in combination
- Non-small cell lung cancer, Advanced